These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 2563233)
41. Prediction of outcome in first-episode schizophrenia. Lieberman JA J Clin Psychiatry; 1993 Mar; 54 Suppl():13-7. PubMed ID: 8097192 [TBL] [Abstract][Full Text] [Related]
42. Dopaminergic activity and idiopathic edema. Franco K; Tamburrino M; Campbell N; Pentz J; Evans C Hosp Community Psychiatry; 1991 Mar; 42(3):309-10. PubMed ID: 1801766 [No Abstract] [Full Text] [Related]
43. Neuroleptic medication facilitates the natural occurrence of tardive dyskinesia. A critical review. Driesens F Acta Psychiatr Belg; 1988; 88(3):195-205. PubMed ID: 2906780 [TBL] [Abstract][Full Text] [Related]
44. The possible role of dopamine autoreceptors in neuroleptic atypicality. Javitt DC; Weinstein SL; Opler LA Psychiatr Dev; 1988; 6(1):57-71. PubMed ID: 2902622 [TBL] [Abstract][Full Text] [Related]
45. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Andrew HG Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668 [TBL] [Abstract][Full Text] [Related]
46. Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopathological variables. Albus M; Naber D; Müller-Spahn F; Douillet P; Reinertshofer T; Ackenheil M Biol Psychiatry; 1985 Oct; 20(10):1082-9. PubMed ID: 2864087 [TBL] [Abstract][Full Text] [Related]
47. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Csernansky JG; Kaplan J; Holman CA; Hollister LE Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793 [TBL] [Abstract][Full Text] [Related]
49. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Chouinard G; Annable L; Jones BD; Collu R Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066 [TBL] [Abstract][Full Text] [Related]
50. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. Kornhuber J; Riederer P; Reynolds GP; Beckmann H; Jellinger K; Gabriel E J Neural Transm; 1989; 75(1):1-10. PubMed ID: 2563750 [TBL] [Abstract][Full Text] [Related]
51. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group. Psychopharmacology (Berl); 1986; 90(4):423-9. PubMed ID: 2880362 [TBL] [Abstract][Full Text] [Related]
52. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Miller R; Chouinard G Biol Psychiatry; 1993 Nov; 34(10):713-38. PubMed ID: 7904833 [TBL] [Abstract][Full Text] [Related]
53. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients. Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385 [TBL] [Abstract][Full Text] [Related]
54. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin. Tripodianakis J; Markianos M; Garelis E Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625 [TBL] [Abstract][Full Text] [Related]
55. Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis. Csernansky JG; Vinogradov S; Prosser E; Kaplan J; Berger PA; Hollister LE Psychopharmacol Bull; 1986; 22(3):897-9. PubMed ID: 2879311 [No Abstract] [Full Text] [Related]
56. The current status of tardive dyskinesia. Sachdev PS Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961 [TBL] [Abstract][Full Text] [Related]
57. RBC and plasma choline in neuroleptic-treated schizophrenic patients. Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429 [TBL] [Abstract][Full Text] [Related]
58. The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal. Newell KM; Wszola B; Sprague RL; Mahorney SL; Bodfish JW Exp Clin Psychopharmacol; 2001 Aug; 9(3):262-8. PubMed ID: 11534536 [TBL] [Abstract][Full Text] [Related]
59. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Chouinard G; Jones BD Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522 [TBL] [Abstract][Full Text] [Related]
60. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. McGrath JJ; Soares KV Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]